Gilgamesh Pharma

Actual: May 1, 2024

Phase 2a first patient dosed (NCT06309277)

Why it matters: Blixeprodil is an oral, first-in-class GluN2B-selective NMDA receptor antagonist (R-enantiomer of 4-fluorodeschloroketamine). By targeting only the GluN2B subunit, it is designed to produce rapid antidepressant effects similar to ketamine while avoiding the dissociative and sedative side effects that limit ketamine's use.

Actual: Jan 6, 2026

Positive topline Phase 2a results announced — statistically significant and clinically meaningful antidepressant effect; rapid onset sustained through observation period; no significant dissociation or sedation

Why it matters: Positive Phase 2a data with a clean safety profile validates the GluN2B-selective mechanism and positions blixeprodil for Phase 2b/3. This is Gilgamesh Pharma's lead asset following the AbbVie acquisition of bretisilocin.

Watch next: Phase 2b or Phase 3 trial design announcement and initiation (2026)

Actual: May 1, 2025

Phase 2a positive: −21.6 MADRS change from baseline vs −12.1 for 1mg comparator at Day 14; no SAEs (NCT06236880)

Why it matters: Bretisilocin (GM-2505, 5F-MET) is a short-acting 5-HT2A agonist and serotonin releaser — a next-generation psychedelic with a rapid, titratable onset. A −21.6 MADRS improvement vs a low-dose active comparator (not placebo) is a strong signal, suggesting a clear dose-response relationship with a clean safety profile.

Actual: Oct 17, 2025

AbbVie acquisition of bretisilocin programme completed (up to $1.2B); announced August 25, 2025; closed October 17, 2025

Why it matters: AbbVie's acquisition at up to $1.2B is the largest psychedelic drug deal in history, validating bretisilocin's commercial potential and signalling Big Pharma's confidence in novel psychedelic therapeutics for MDD.

Watch next: AbbVie Phase 2b/3 programme design and initiation under AbbVie leadership

Likely: Q3 2026

Why it matters: Phase 1 will establish the cardiac safety profile of GM-3009 vs ibogaine — the primary question for the field. NIDA funding removes commercial risk from the Phase 1 stage.

Actual: Jan 1, 2025

$14M NIDA grant awarded for IND-enabling studies, GMP manufacturing, and Phase 1/Ib trials

Why it matters: GM-3009 is a cardio-safe ibogaine analog (noribogaine-related, kappa-opioid receptor agonist with neuroplastogenic properties) designed to retain ibogaine's anti-addiction effects while eliminating QTc prolongation — the key safety barrier. NIDA's $14M grant is one of the largest NIDA awards in the psychedelic space and strongly validates the scientific case.

Watch next: IND filing and Phase 1 FIH study initiation (2026)

Why it matters: M1/M4 muscarinic agonism is now a validated schizophrenia mechanism following the 2024 FDA approval of xanomeline-trospium (KarXT/Cobenfy, Bristol Myers Squibb). Gilgamesh's programme targets the same pathway, potentially with improved selectivity or tolerability vs KarXT.

Watch next: Lead compound selection and IND-enabling timeline